Efficacy, Practicality, and Safety of Inhaled Methoxyflurane in Elderly Patients with Acute Trauma Pain: Subgroup Analysis of a Randomized, Controlled, Multicenter, Open-Label Trial (MEDITA)

Figures & data

Table 1 Baseline Characteristics

Characteristics		Methoxyflurane (N=35)	Standard Analgesic Treatment (SAT) (N=34)
Age (years)	Mean (SD)	75 (6.8)	76,4 (7.7)
	Range	65–91	65–95
Gender [n (%)]	Male	5 (14)	6 (18)
	Female	30 (86)	28 (82)
Weight (kg)	Mean (SD)	69 (10.2)	69 (10.3)
	Range	50–94	50–85
Race [n (%)]	Caucasian	34 (97)	34 (100)
	Asian	1 (3.0)	0
	Black	0	0
	Other	0	0
Baseline pain group [n (%)]	Moderate [NRS 4–6]	18 (51)	19 (56)
	Severe [NRS ≥7]	17 (49)	15 (44)
Suspected injury type at inclusion [n (%)]	Contusion	15 (43)	15 (44)
	Fracture	15 (43)	13 (38)
	Dislocation	5 (14)	5 (15)
	Crushing	0	1 (3)

Figure 1 Pain reduction. Mean ± standard error. n=69. SAT: standard analgesic treatment (moderate pain: IV paracetamol or IV ketoprofen; severe pain: IV morphine).

Figure 2 Time to pain relief.

Figure 3 Overall treatment efficacy evaluated by patients and practicality by HCPs. Cumulative proportions of 5-point Likert qualitative scale (“Poor”, “Fair”, “Good”, “Very Good”, or “Excellent”) at 30 min after randomization. SAT: standard analgesic treatment (moderate pain: IV paracetamol or IV ketoprofen; severe pain: IV morphine). P-value = 0.04 (Mann–Whitney U-test).

Table 2 Adverse Events

Adverse Events	Paracetamol (N=16)	Paracetamol – %	Methoxyflurane (N=35) – N	Methoxyflurane – %	Total (N=69) – N	Total – %
Vertigo	0	0.0%	1	2.9%	1	1.4%
Constipation	1	6.3%	0	0.0%	1	1.4%
Nausea	1	6.3%	2	5.7%	3	4.3%
Vomiting	1	6.3%	0	0.0%	1	1.4%
Bronchitis	0	0.0%	1	2.9%	1	1.4%
Presyncope	2	12.5%	1	2.9%	3	4.3%
Somnolence	0	0.0%	1	2.9%	1	1.4%
Hyperhidrosis	1	6.3%	0	0.0%	1	1.4%
Hypotension	1	6.3%	0	0.0%	1	1.4%